Ventana Medical Systems

Summary

Ventana Medical Systems, Inc. was a medical device company that develops, manufactures, and markets instrument reagent systems that automate tissue and slide staining in anatomic pathology laboratories. These products assist in the diagnosis and treatment of cancer and infectious diseases.[1]

Ventana Medical Systems, Inc.
Company typeSubsidiary
IndustryMedical
Founded1985
FounderThomas Grogan, M.D.
Headquarters,
Area served
Worldwide
Key people
Thomas Grogan, M.D (Founder)
ProductsMedical equipment
Assay development
ServicesClinical laboratory
Number of employees
1,500
ParentF. Hoffmann-La Roche Ltd.
DivisionsRoche Diagnostics
Websitewww.ventana.com

The company is now part of the Roche Diagnostics Division and has been renamed Roche Tissue Diagnostics. [2]

Company history edit

Pathologist and University of Arizona professor Thomas Grogan, M.D., founded Ventana in 1985. The company launched its first instrument reagent system in 1991, and held an initial public offering (IPO) in 1996, trading under the symbol VMSI on the NASDAQ stock exchange.[3]

In 2007, Ventana acquired Spring BioScience Corp, a developer and supplier of monoclonal antibodies.[4] That same year, Ventana rejected a hostile takeover bid from Roche Holding AG for $75 a share.[5] In February 2008, Roche acquired Ventana with a cash offer of $89.50 per share ($3.4 billion).[5]

Key people edit

Products edit

Ventana manufactures products within eight areas:

References edit

  1. ^ "Ventana Medical Systems Inc". Bloomberg. Retrieved 2012-11-09.
  2. ^ "Roche Tissue Diagnostics".
  3. ^ "Ventana Medical Systems". BioPortfolio. Retrieved 2012-11-03.
  4. ^ Sherman, Debra (2007-09-05). "Ventana buys Spring Bioscience, raises outlook". Reuters. Retrieved 2012-11-03.
  5. ^ a b Doherty, Dermot (January 22, 2008). Roche’s Higher Offer Wins Ventana After Seven Months (Update11). Bloomberg. Retrieved November 3, 2012.